Recursion Pharmaceuticals... (RXRX)
NASDAQ: RXRX
· Real-Time Price · USD
4.75
-0.95 (-16.67%)
At close: May 05, 2025, 3:59 PM
4.80
1.05%
After-hours: May 05, 2025, 07:59 PM EDT
-16.67% (1D)
| Bid | 4.7 |
| Market Cap | 1.88B |
| Revenue (ttm) | 58.8M |
| Net Income (ttm) | -463.49M |
| EPS (ttm) | -1.69 |
| PE Ratio (ttm) | -2.81 |
| Forward PE | -3.84 |
| Analyst | Hold |
| Ask | 4.8 |
| Volume | 32,792,937 |
| Avg. Volume (20D) | 25,128,341 |
| Open | 5.45 |
| Previous Close | 5.70 |
| Day's Range | 4.75 - 5.80 |
| 52-Week Range | 3.79 - 12.36 |
| Beta | 0.99 |
About RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 16, 2021
Employees 800
Stock Exchange NASDAQ
Ticker Symbol RXRX
Website https://www.recursion.com
Analyst Forecast
According to 5 analyst ratings, the average rating for RXRX stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 68.42% from the latest price.
Stock ForecastsEarnings Surprise
Recursion Pharmaceuticals has released their quartely earnings
on May 5, 2025:
Next Earnings Release
Recursion Pharmaceuticals Inc. is scheduled to release its earnings on May 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
-16.49%
Recursion Pharmaceuticals shares are trading lower...
Unlock content with
Pro Subscription
1 week ago
-0.89%
RXRX stock has given up its prior gain. Recursion Pharmaceuticals shares were trading higher after the company unveiled preliminary clinical data for REC-4881.
